

# Progestins Regulate the Expression and Activity of the Forkhead Transcription Factor FOXO1 in Differentiating Human Endometrium

Soraya Labied,\* Takeshi Kajihara,\* Patricia A. Madureira, Luca Fusi, Marius C. Jones, Jenny M. Higham, Rana Varshochi, Julia M. Francis, Georgia Zoumpoulidou, Abdelkader Essafi, Silvia Fernandez de Mattos, Eric W.-F. Lam, and Jan J. Brosens

*Institute of Reproductive and Developmental Biology (S.L., T.K., L.F., M.C.J., J.M.F., G.Z., J.J.B.), Wolfson and Weston Research Centre for Family Health, and Cancer Research-United Kingdom Laboratories and Section of Cancer Cell Biology (P.A.M., R.V., A.E., S.F.d.M., E.W.-F.L.), Department of Cancer Medicine, Imperial College London, Hammersmith Hospital, London W12 ONN, United Kingdom; and Department of Obstetrics and Gynaecology (J.M.H.), Imperial College London, St. Mary's Hospital, London W2 1PG, United Kingdom*

**Menstruation, or cyclic shedding of nonpregnant endometrial tissue with associated bleeding, occurs only in humans and a few other species. This breakdown of the endometrium in response to falling ovarian progesterone levels is a complex process, characterized by local leukocyte infiltration, expression and activation of matrix metalloproteinases, and apoptosis. Spontaneous decidualization (differentiation) of the stromal compartment precedes the cyclic shedding of the endometrium in various menstruating species but the mechanisms that link these processes are not understood. In this study, we identified FOXO1 as a key transcription factor responsible for mediating apoptosis of decidualized human endometrial stromal cells (HESCs) in response to progesterone withdrawal. We demonstrate that medroxyprogesterone ace-**

**tate (MPA, a synthetic progestin) enhances the expression of FOXO1 in differentiating HESCs while simultaneously inducing cytoplasmic retention and inactivation of FOXO1. Withdrawal of MPA from decidualized HESCs results in rapid nuclear accumulation of FOXO1, increased *BIM* expression, a proapoptotic FOXO1 target gene, and cell death. Conversely, silencing of FOXO1 expression completely abolishes cell death induced by MPA withdrawal. In summary, the observation that differentiating HESCs become dependent on progesterone signaling for survival through induction and reversible inactivation of FOXO1 suggests a novel mechanism that links decidualization of the endometrium to menstruation. (*Molecular Endocrinology* 20: 35–44, 2006)**

**D**ECIDUALIZATION REPRESENTS the process of morphological and biochemical differentiation of the endometrial stromal compartment that occurs in all species in which embryo implantation involves breaching of endometrial surface epithelium (1, 2). Decidualization is essential for the formation of a functional placenta and, in most species, this differentiation process is triggered by signals derived from the implanting blastocyst (3). However, in humans and other menstruating primates, decidual transformation of the upper (functional) endometrial layer occurs in the midsecretory phase of the cycle independently of

the presence of a conceptus (2, 4, 5). In the absence of pregnancy, luteolysis and falling ovarian progesterone levels elicit a cascade of events in the endometrium of menstruating species, leading to proteolytic breakdown, shedding of the functional layer, and bleeding. This complex but coordinated process involves local expression of chemokines and proinflammatory cytokines, influx of leukocytes, expression and activation of matrix metalloproteinases, and loss of the decidualized phenotype (6–9). Apoptosis, first apparent in epithelial cells and then in a proportion of the decidualized stromal cells, is another cardinal feature of impending menstruation (10, 11).

The notion that decidualization in the absence of pregnancy is causally linked to menstruation is supported by several other lines of evidence. For instance, spontaneous decidualization also occurs in the few nonprimate species known to menstruate, such as the black mastiff bat (*Molossus ater*) (12). In ovariectomized mice, withdrawal of progesterone support induces tissue breakdown but only if the endometrium has first been artificially decidualized (13). Furthermore, the decidual process in humans starts around the terminal spiral ar-

## First Published Online August 25, 2005

\* S.L. and T.K. contributed equally to the work.

Abbreviations: Bim, Bcl-2 interacting mediator; 8-brcAMP, 8-bromoadenosine-cAMP; HESC, human endometrial stromal cell; MPA, medroxyprogesterone acetate; PARP, poly(ADP-ribose) polymerase; PI3K, phosphatidylinositol 3-kinase; siRNA, short interfering RNA.

***Molecular Endocrinology* is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.**

teries and coincides with expression of various factors implicated in tissue hemostasis. For example, decidualized stromal cells highly express tissue factor, the initiator of the extrinsic coagulation pathway, and plasminogen activator inhibitor-1, which limits fibrinolysis by inhibiting both tissue-type and urokinase-type plasminogen activator (14, 15). Consequently, apoptosis and loss of the decidual phenotype upon progesterone withdrawal promote focal bleeding and menstruation.

High progesterone levels are absolutely necessary for maintaining the decidual phenotype before menstruation and during pregnancy. However, several studies have shown that initiation of this differentiation process requires elevated cAMP levels and sustained activation of the protein kinase A pathway (16–18). We recently reported that activation of the cAMP second messenger pathway in human endometrial stromal cells (HESCs) induces the expression of FOXO1, a member of the FOXO subfamily of Forkhead transcription factors (19). FOXO family members, FOXO1, FOXO3a, and FOXO4, are direct downstream targets of the phosphatidylinositol 3-kinase (PI3K)/Akt signal transduction pathway (20, 21). Phosphorylation of FOXO proteins by Akt results in cytoplasmic retention and inhibition of their transcriptional activity. Depending on the cellular context, activated FOXO proteins have been shown to induce expression of genes that encode for proteins involved in cell cycle inhibition, such as p27<sup>kip1</sup> and p130-Rb2, or proapoptotic proteins including Bim (Bcl-2 interacting mediator), TRAIL (TNF- $\alpha$ -related apoptosis-inducing ligand), and Fas ligand (22–26).

We now demonstrate that, upon decidualization, endometrial cells become dependent upon progesterone signaling for survival through induction, cytoplasmic translocation, and inactivation of FOXO1. Withdrawal of progesterone from differentiated cultures results in nuclear reaccumulation of FOXO1, enhanced Bim expression, and cell death. Together, the data demonstrate a critical role for progesterone as a survival factor for decidualized endometrium and provide novel insights into the molecular pathways that control the onset of menstruation.


## RESULTS

cAMP and progesterone signaling differentially regulate the expression of FOXO1 and FOXO3a in HESCs. To investigate the role of FOXO proteins in human endometrium, we first profiled their expression in undifferentiated and decidualizing HESCs. Primary cultures were treated with either 8-bromoadenosine-cAMP (8-br-cAMP), the progestin MPA (medroxyprogesterone acetate), or a combination for 1 or 3 d and harvested for mRNA and protein analyses (Fig. 1, A and B). As expected, 8-br-cAMP induced the expression of FOXO1 mRNA and protein in HESCs (19) but, interestingly, this response was markedly enhanced by MPA. Treatment with MPA alone did not induce

FOXO1 expression but up-regulated FOXO3a mRNA and protein levels although not when cells were co-treated with 8-br-cAMP. FOXO4 transcripts were present in HESCs, but we found no evidence of expression at protein level by Western blot analysis (Fig. 1B). The differential regulation of FOXO proteins upon HESC differentiation *in vitro* reflected the expression patterns determined *in vivo*. Analysis of timed endometrial biopsies showed an approximately 4-fold increase in the abundance of FOXO1 transcripts during the midsecretory phase of the cycle (Fig. 1C). Elevated FOXO1 mRNA levels were maintained in late-secretory or premenstrual endometrium. In contrast, the abundance of FOXO3a transcripts appeared to decline before menstruation whereas FOXO4 mRNA levels did not exhibit cycle-dependent regulation (Fig. 1C). Enhanced FOXO1 mRNA levels in mid- and late-secretory endometrium coincided with strong FOXO1 immunostaining in the stromal compartment (Fig. 1D). In contrast, there was little or no FOXO3a or FOXO4 immunoreactivity in the stromal compartment at any stage of the cycle (Fig. 1D).

### Progesterone Inhibits BIM Expression

Having established that FOXO1 is the predominant FOXO family member in differentiating human endometrium, we examined whether its expression profile correlated with that of *BIM* (*BCL2L11*), a known FOXO target gene that encodes for a proapoptotic Bcl-2 homology 3 domain-only protein (24, 25). Although Bim transcripts were present in endometrial samples throughout the cycle, their abundance increased only in the premenstrual phase of the cycle (Fig. 2A). Immunohistochemical analysis of late-secretory endometrium showed marked Bim staining in endometrial surface epithelium as well as the adjacent stroma (Fig. 2B). In culture, Bim mRNA and protein were induced upon treatment with 8-br-cAMP (Fig. 2, C and D), mirroring the expression of FOXO1. However, whereas addition of MPA to 8-br-cAMP-treated cultures enhanced FOXO1 protein levels, *BIM* expression was inhibited (Fig. 2D). This was paradoxical given that several lines of evidence indicated that *BIM* is regulated by FOXO1 in HESCs. First, transiently transfected FOXO1 activated the wild-type *BIM* promoter coupled to a luciferase reporter in HESCs but not a mutant *BIM* promoter construct in which the FOXO1 consensus sequence, located between –164/–170 relative to the transcription start site (27), was altered (data not shown). Second, DNA-pull down experiments demonstrated that endogenous FOXO1 is recruited to the FOXO-binding site of the *BIM* promoter in 8-br-cAMP-stimulated cultures although not in cells cotreated with MPA. No binding was observed to a mutated FOXO-response element (Fig. 2E). Finally, silencing of endogenous FOXO1 expression by small interfering RNA (siRNA) abrogated *BIM* expression in 8-br-cAMP or 8-br-cAMP plus MPA-treated HESCs (data not shown and Fig. 2F).




**Fig. 1.** Expression and Regulation of FOXO Proteins in Differentiating Human Endometrium

A, RTQ-PCR analysis of FOXO1, FOXO3a, and FOXO4 transcript levels in HESCs treated with 8-br-cAMP (cAMP), MPA, or combination for 1 or 3 d. B, Western blot analysis of FOXO proteins in whole-cell lysates obtained from primary HESC cultures treated as indicated. Protein extracts from cells transiently transfected with an FOXO4 expression vector were used as a positive control (+C).  $\alpha$ -Tubulin served as a loading control. C, RTQ-PCR analysis of the various FOXO transcripts in endometrial biopsies obtained from different phases of the cycle: proliferative (P; n = 8), early secretory (ES; n = 8), midsecretory (MS; n = 6), and late secretory (LS; n = 7). Error bars are  $\pm$ sd. D, FOXO immunostaining in proliferative (D8) and late-secretory (D25) endometrium (original magnification:  $\times$ 100). Rhabdomyosarcoma tissue sections were used as a positive control (+C) for FOXO3a and FOXO4 immunostaining (insets). D8, day 8; D25, day 25.

### Progesterone Induces Cytoplasmic Translocation of FOXO1

Phosphorylation of FOXO proteins, in response to activation of the PI3K/Akt signaling pathway or other kinases, leads to their retention in the cytoplasm and,

consequently, transcriptional inactivation (21, 28). We speculated that the opposing effects of MPA on FOXO1 expression and transcriptional activity in 8-br-cAMP-treated HESCs could reflect changes in the subcellular distribution of FOXO1. Confocal microscopy demonstrated that this was indeed the case (Fig.




**Fig. 2.** MPA Inhibits FOXO1-Mediated *BIM* Expression in Decidualizing HESCs

A, Relative level of *Bim* mRNA expression, measured by RTQ-PCR, in proliferative (P;  $n = 9$ ), early-secretory (ES;  $n = 9$ ), midsecretory (MS;  $n = 6$ ), and late-secretory (LS;  $n = 7$ ) endometrial biopsies. *Error bars* indicate  $\pm$ sd. B, *Bim* immunostaining in proliferative (d 8) and premenstrual (d 27) endometrium. Original magnification:  $\times 100$ . C, Relative expression of *Bim* transcripts in undifferentiated HESCs and cells stimulated as indicated for either 1 or 3 d. D, *Bim* expression in total protein extracts from untreated HESCs or cells treated for 3 d as indicated were analyzed by Western blot analysis.  $\beta$ -Actin expression was used as a loading control. E, Nuclear protein extracts from HESCs treated for 3 d as indicated were incubated with a 5'-biotinylated double-stranded oligonucleotide corresponding to the  $-139$  to  $-145$  region of the *BIM* promoter (*Bim*-wt oligo) or biotinylated oligonucleotide in which the FOXO-binding site was mutated (*Bim*-mt oligo). DNA-bound proteins were pulled down and immunoblotted for FOXO1. F, Mock transfected HESCs or cells transfected with FOXO1 siRNAs, lamin A/C siRNA, or nontargeting (control) siRNAs were treated as indicated for 3 d. Whole-cell lysates were used to examine expression of FOXO1, *Bim*, and lamin A/C by Western blot analysis.

3A). Endogenous FOXO1 immunoreactivity in 8-br-cAMP-treated cells was confined to distinct punctate nuclear structures, but cotreatment of cells with MPA resulted in cytoplasmic retention of FOXO1. Notably, discrete FOXO1 foci remained apparent in nuclei of cells treated with 8-br-cAMP and MPA (Fig. 3A). Western blot analysis of cytoplasmic and nuclear protein fractions confirmed that MPA induces phosphorylation and cytoplasmic accumulation of FOXO1 in 8-br-cAMP-treated cells, which coincided with elevated levels of activated (phosphorylated) Akt (Fig. 3B). As reported previously, total Akt levels were lower in cells treated with 8-br-cAMP alone (29). Treatment of decidualized cells with the PI3K inhibitor LY294002 abrogated Akt and FOXO1 phosphorylation, indicating that the cytoplasmic translocation of FOXO1 in the presence of MPA is mediated by the PI3K/Akt signaling pathway.

### Apoptosis of Decidualized Cells in Response to Progesterone Withdrawal Is Mediated by FOXO1

We investigated whether withdrawal of MPA from decidualized cultures would restore FOXO1 activity and increase cell death. To test this, we first monitored the expression of *Bim* in primary cultures treated with 8-br-cAMP and MPA for 3 d followed by selective withdrawal of the differentiation stimuli for 24 h (Fig. 4A). Western blot analysis showed that withdrawal of MPA alone substantially increased *Bim* levels whereas withdrawal of both 8-br-cAMP and MPA from the cultures only marginally increased the expression levels. Surprisingly, withdrawal of 8-br-cAMP for 24 h did not substantially lower *Bim* protein levels, which may reflect protein stability. Flow cytometry of parallel cultures stained with propidium iodide demonstrated a 2.5-fold increase in the number of dead or dying cells,




**Fig. 3.** Progesterins Induce FOXO1 Phosphorylation and Cytoplasmic Retention in Differentiating HESCs

A, Confocal microscopy demonstrating endogenous FOXO1 expression in cells treated for 3 d with 8-br-cAMP (cAMP) in the presence or absence of MPA. Arrowheads indicate residual nuclear FOXO1. B, Western blot analysis of Bim, FOXO1, phosphorylated FOXO1 (p-FOXO1; Ser256), Akt, and phosphorylated Akt (p-Akt; Ser473) expression in the cytosolic (cyt.) or nuclear (nuc.) compartments of untreated cells or cells treated as indicated for 3 d. C, HESCs were treated with 8-br-cAMP plus MPA (cAMP/MPA) for 3 d. Subsequently, some cultures were treated with LY294002 for 2 h. Cytosolic protein fractions were analyzed by immunoblotting. DAPI, 4',6-Amidino-2-phenylindole.

containing less than 2 n DNA, upon withdrawal of MPA from decidualized cultures (Fig. 4, B and C). In contrast, withdrawal of 8-br-cAMP had no effect, whereas withdrawal of both 8-br-cAMP and MPA marginally increased the apoptotic fraction. Overall, the level of Bim expression correlated well with the degree of cell death. Two lines of evidence demonstrated that apoptosis of decidualized cells upon progestin withdrawal is mediated by FOXO1. First, MPA withdrawal increased the nuclear FOXO1 levels while simultaneously lowering expression in the cytoplasmic compartment (Fig. 4D). Notably, nuclear reaccumulation of FOXO1 was a rapid event, apparent as early as 1 h after MPA withdrawal (Fig. 4D), and preceded the expression of apoptotic markers such as cleaved poly(ADP-ribose) polymerase (PARP)-1 and cleaved caspase-3 (data not shown). Second, knock-down of FOXO1 expression by siRNA lowered the basal apoptosis levels and completely abolished the ability of differentiated HESCs to undergo programmed cell death in response to progestin withdrawal (Fig. 4, E and F).

## DISCUSSION

The three human FOXO proteins are homologs of DAF-16 in *Caenorhabditis elegans*, an important regulator of longevity in this organism (30). In mammalian cells, FOXO proteins are critical mediators of cell fate decisions, such as cell cycle arrest, senescence, and apoptosis, in response to growth factor, and hormonal and environmental cues (31, 32). FOXO proteins are ubiquitously expressed in many cell types. In normal cycling human endometrium, however, FOXO1 is the predominant isoform, and its expression is restricted to the epithelial and stromal compartments during the luteal phase of the cycle. Using primary cultures, we demonstrated that decidualization in response to activation of the cAMP second messenger pathway coincides with the expression of FOXO1. Surprisingly, whereas MPA treatment led to a further increase in FOXO1 levels, FOXO1 transcriptional activity was inhibited as a result of targeted phosphorylation and cytoplasmic retention. FOXO1 phosphorylation in re-



**Fig. 4.** Progesterin Withdrawal from Decidualizing Cells Results in Nuclear Accumulation of FOXO1 and Increased Cell Death

A, Western blot analysis of Bim protein levels in untreated HESCs and in decidualized cells (pretreated with 8-br-cAMP and MPA for 3 d) upon 24-h withdrawal of the differentiation stimuli, as indicated. B, Cell cycle analysis of 8-br-cAMP and MPA-pretreated HESCs upon withdrawal of either 8-br-cAMP, MPA, or both from the cultures for 24 h. The percentage of cells in each phase of the cell cycle (<2N, G<sub>0</sub>/G<sub>1</sub>, S, and G<sub>2</sub>/M) is indicated. C, Mean fold increase (F.I.) in the apoptotic fraction of four separate decidualizing cultures upon 24-h withdrawal of MPA. Error bars are  $\pm$ sd. D, Western blot analysis demonstrating the relative levels of FOXO1 in cytosolic and nuclear protein fractions of decidualized cells harvested at various time points after MPA was withdrawn from the cultures. E, Mock transfected HESCs or cells transfected with FOXO1 siRNAs, lamin A/C siRNA, or nontargeting (control) siRNAs were treated for 3 d with 8-br-cAMP and MPA (cAMP/MPA) whereupon MPA was withdrawn (-MPA) from some cultures for 24 h. F, Percent change in the apoptotic index of mock transfected HESCs or cells transfected with FOXO1 siRNAs, lamin A/C siRNA, or nontargeting (control) siRNA after 24 h of MPA withdrawal.

sponse to MPA was dependent upon PI3K/Akt activation. This is most likely an autocrine effect as progesterone is known to enhance the expression of a variety of growth factors in differentiating HESCs, including epidermal growth factor, vascular epithelial growth factor, and IGF-I, capable of activating this signal transduction pathway (33, 34).

PI3K/Akt-mediated phosphorylation and nuclear export of FOXO1 have been shown to trigger proteasomal degradation (35, 36). Recent data suggest that Skp2, an oncogenic subunit of the Skp1/Cul1/F-box protein complex, directs FOXO1 ubiquitination and proteasome degradation (37). In human endometrium, the expression of this E3 ubiquitin ligase is markedly down-regulated during the secretory phase of the cycle (38), suggesting that reduced degradation may contribute to the cytoplasmic accumulation of FOXO1 in decidual cells. Notably, this cytoplasmic translocation was partial, and a discernible amount of FOXO1 remained detectable in the nuclei of cAMP- and MPA-treated cells. Based on expression of recombinant proteins and promoter-reporter systems, it has been suggested that FOXO1, through its ability to bind other transcription factors such as C/EBP $\beta$  and HOXA10, regulates the expression of two major decidua-specific genes, *prolactin (PRL)* and *IGF-binding protein 1 (IGFBP1)* (19, 39). Whether endogenous FOXO1 is indeed involved in multimeric complexes that drive the promoters of these genes is currently under investigation.

Withdrawal of MPA from decidualized cultures elicited reaccumulation of FOXO1 in the nucleus and increased cell death. Previous studies have implicated *Fas ligand (FASLG)*, also a FOXO target gene, in regulating HESC apoptosis (40, 41). However, several lines of evidence presented in this study indicate that Bim may also be involved in effecting perimenstrual endometrial apoptosis. First, we demonstrated that *BIM* is a *bona fide* FOXO1 target gene in HESCs. Second, Bim expression is up-regulated in decidualized cultures upon MPA withdrawal and, most relevantly, its expression *in vivo* increases premenstrually when progesterone levels decline. Notably, FOXO1 and Bim are also expressed in the epithelial cells in late secretory endometrium. In contrast to the stroma, progesterone receptor levels are markedly down-regulated in epithelial cells before menstruation, which could account for the earlier onset and higher apoptotic index in this compartment (10).

Cyclic decidualization and menstrual shedding occur on average 400 times during the reproductive years of women in developed countries (8). Consequently, abnormal uterine bleeding is one of the most common disorders in women and a major indication for surgical intervention such as hysterectomy or endometrial ablation (5). The unique ability of FOXO1 to regulate HESC survival and apoptosis suggests that it might be a useful therapeutic target for menstrual disorders. Selective regulators of FOXO expression and nuclear transport, currently being developed for the

treatment of a variety of cancers (42), may also be useful in the treatment of other gynecological disorders, including endometriosis. This debilitating condition is characterized by ectopic growth of endometrial tissue and affects 5–10% of women of reproductive age (43). A recent study demonstrated that FOXO1 mRNA levels are lower in secretory endometrium of women with endometriosis when compared with healthy controls (44). Others have reported that apoptosis is markedly reduced in premenstrual endometrium of endometriosis patients as well as in the endometriotic lesions (45, 46). This raises the possibility that dysregulation of FOXO1 expression or activity contributes to implantation, survival, and growth of ectopic endometrium. Furthermore, 50–80% of endometrial cancers harbor a mutation in the *PTEN* tumor suppressor gene, the highest incidence of *PTEN* mutation in any tumor type analyzed to date (47, 48). *PTEN* encodes a lipid phosphatase that specifically dephosphorylates the D3 position of phosphatidylinositol 3,4,5-triphosphate and, in so doing, functionally antagonizes the PI3K/Akt pathway. Whether inactivation of FOXO proteins constitutes the link between loss of PTEN function, constitutive activation of the PI3K/Akt pathway and endometrial tumorigenicity is currently under investigation.

Understanding the mechanisms of menstruation is of paramount importance given the enormous health burden associated with abnormal uterine bleeding. Our study demonstrates how progesterone acquires the role of a survival factor upon decidualization of the human endometrium through the regulation of FOXO1 expression and activity. To what extent this mechanism is perturbed in menstrual disorders remains to be determined. However, the pivotal role of FOXO1 in regulating endometrial apoptosis upon progesterone withdrawal suggests that it could be a useful therapeutic target.

## MATERIALS AND METHODS

### Tissue Collection and Primary Culture

The Local Research and Ethics Committee approved this study, and patient consent was obtained before tissue collection. Endometrial samples from cycling women without uterine pathology were divided for histological dating, using standard criteria, and for storage in RNAlater (Ambion, Inc., Austin, TX). Endometrial samples were classed as proliferative, early secretory (d 15–19), midsecretory (d 20–23) or late secretory (d 24 or later). HESCs were isolated from fresh biopsies and primary cultures were established, maintained, and decidualized with 0.5 mM 8-br-cAMP (Sigma Chemical Co., St. Louis, MO) and  $10^{-6}$  M MPA (Sigma) as previously described (49, 50). All experiments were carried out before the third cell passage.

### Real-Time Quantitative PCR

Total RNA extracted from untreated or decidualizing HESC cultures and from tissue samples stored in RNAlater (Am-

bion), was reversed transcribed, and the resulting cDNA was amplified using an ABI Prism 7700 Sequence Detection System (Applied Biosystems, Foster City, CA) (49) and the following gene-specific primer pairs: *FOXO1*-sense (TGG ACA TGC TCA GCA GAC ATC) and *FOXO1*-antisense (TTG GGT CAG GCG GTT CA); *FOXO3a*-sense (CCC AGC CTA ACC AGG GAA GT) and *FOXO3a*-antisense (AGC GCC CTG GGT TTG G); *FOXO4*-sense (CCT GCA CAG CAA GTT CAT CAA) and *FOXO4*-antisense (TTC AGC ATC CAC CAA GAG CTT); *BIM*-sense (ATC TCA GTG CAA TGG CTT CC) and *BIM*-antisense (CAG GCG GAC AAT GTA ACG TA); *L19*-sense (GCG GAA GGG TAC AGC CAA T) and *L19*-antisense (GCA GCC GGC GCA AA). *L19*, a nonregulated ribosomal house-keeping gene, served as an internal control and was used to normalize for differences in input RNA. All measurements were performed in triplicate.

### Western Blot Analysis

Whole-cell extracts or nuclear and cytoplasmic protein fractions were immunoblotted as described elsewhere (17, 49). In some experiments, cells were treated with LY294002 (20  $\mu$ M) for 2 h before harvesting. Antibodies to FOXO1 (Cell Signaling Technology, Beverly, MA), FOXO3a (Upstate Biotechnology, Inc., Lake Placid, NY), FOXO4 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), Bim (Calbiochem, La Jolla, CA), phospho-FOXO1 (Ser256) (Cell Signaling), Akt (Cell Signaling), phospho-Akt (Ser473) (Cell Signaling), PARP Cleavage site (214/215) (Biosource Technologies, Inc., Camarillo, TX), PARP (F-2) (Santa Cruz Biotechnology), Lamin A/C (636) (Santa Cruz Biotechnology), and  $\alpha$ -Tubulin (TU-02) (Santa Cruz Biotechnology) were used at 1:1,000 whereas the antibody to  $\beta$ -Actin (Abcam, Cambridge, UK) was diluted 1:40,000.

### Immunohistochemistry, Confocal Microscopy, and Flow Cytometry

Paraffin-embedded, formalin-fixed endometrial specimens, obtained at various stages of the cycle, were examined *in vivo* FOXO and Bim immunoreactivity. Sections (5  $\mu$ m), placed on 1% (wt/vol) polylysine slides, were deparaffinized, dehydrated, exposed to 0.3% (vol/vol) H<sub>2</sub>O<sub>2</sub> for 15 min, and subsequently microwaved in 0.01 M citrate buffer, pH 6.0. Immunostaining was carried out using antibodies to FOXO1 (1:400), FOXO3a (1:800), or FOXO4 (1:400), biotinylated horse anti-goat Ig (1:500), and peroxidase-labeled streptavidin (1:500). Primary antibodies were from Santa Cruz Biotechnology. Vaginal rhabdomyosarcoma tissue sections were used as positive control. Immunostaining for Bim was carried out using antihuman Bim antibody (1:600; Calbiochem) and peroxidase-conjugated goat anti-rabbit IgG (1:200; Vector Laboratories, Inc., Burlingame, CA). In control slides, the primary antibody was replaced with normal goat or rabbit IgG. Confocal microscopy of primary cultures was performed as described elsewhere (49) using antibodies to FOXO1 (1:200; Santa Cruz Biotechnology) and cleaved caspase-3 (Asp175) (1:100; Cell Signaling). Flow cytometry analysis was used to quantify apoptosis in primary cultures by evaluating the sub-G<sub>1</sub> fraction (<2 N) after propidium iodide staining of ethanol-fixed cells (25, 27).

### Oligonucleotide Pull-Down Assay

Nuclear extracts were prepared from cultured cells using the high-salt buffer [20 mM HEPES-KOH (pH 7.9), 25% (vol/vol) glycerol, 420 mM NaCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM EDTA, 0.5 mM dithiothreitol; and 1 mM phenylmethylsulfonylfluoride]. After diluting with 2 vol of low-salt lysis buffer (10 mM HEPES-KOH, pH 7.9; 1.5 mM MgCl<sub>2</sub>; 10 mM KCl; 0.5 mM dithiothreitol; and 1 mM phenylmethylsulfonylfluoride), 50  $\mu$ g of the cell extracts

was incubated at 30 C for 10 min with either 0.5 nmol of the 5'-biotinylated double-stranded wild-type (5'-CAGAGT-TACTCCGGTAAACACGCCAGGGAC-3') or mutant (5'-CAGAGT-TACTCCGGTAGGCACGCCAGGGAC-3') oligonucleotides (Invitrogen) previously coupled to streptavidin agarose beads (Sigma). The wild-type oligonucleotide corresponded to the region of -183 to -154 of the human *Bim* promoter (27). After incubation, the biotinylated oligonucleotide-coupled streptavidin beads were washed at least six times with low-salt buffer containing 150 mM NaCl, denatured in sodium dodecyl sulfate-sample buffer, and immunoblotted for FOXO1.

### Transient Transfection and siRNA

HESCs cultured in 24-well plates were transiently transfected, using calcium phosphate precipitation as described previously (49), with either wild-type or mutant *BIM* promoter-reporter constructs (27) (400 ng/well) and a FOXO1 expression vector (100 ng/well). Cells were harvested for luciferase assay 24 h later. A  $\beta$ -galactosidase control expression vector was cotransfected to control for transfection efficiency. Transfections were performed in triplicate and repeated at least three times. For gene silencing, undifferentiated or decidualized HESCs were transiently transfected with 50 nM of the following siRNA reagents purchased from Dharmacon (Lafayette, CO): FOXO1 siGENOME SMARTpool, siCONTROL Non-Targeting siRNA Pool, or siCONTROL Lamin A/C siRNA.

### Acknowledgments

We thank B. Ainaba, M. Mohammed, A. Aziz, and J. O. White for technical assistance; M. G. Parker, R. White, F. Frankenne, and J. M. Foidart for critical comments; and O. Ishihara for continuous support.

Received July 6, 2005. Accepted August 16, 2005.

Address all correspondence and requests for reprints to: Jan Brosens, Institute of Reproductive and Developmental Biology, Wolfson & Weston Research Centre for Family Health, Imperial College London, Faculty of Medicine, Hammersmith Hospital, London W12 0NN, United Kingdom. E-mail: j.brosens@imperial.ac.uk.

This work was supported by grants from the Wellcome Trust (to J.J.B.), the Daiwa Foundation (to T.K.) and by grants from the "Région Wallonne" (FIRST Europe, Objectif 3, No. EPH3310300R0212/215267, "ENDOMMP"), the Fondation Léon Frédéricq (Université de Liège), and the Belgian Fonds National de la Recherche Scientifique (to S.L.).

### REFERENCES

1. Brosens JJ, Pijnenborg R, Brosens IA 2002 The myometrial junctional zone spiral arteries in normal and abnormal pregnancies: a review of the literature. *Am J Obstet Gynecol* 187:1416–1423
2. Finn CA 1998 Menstruation: a nonadaptive consequence of uterine evolution. *Q Rev Biol* 73:163–173
3. Dey SK, Lim H, Das SK, Reese J, Paria BC, Daikoku T, Wang H 2004 Molecular cues to implantation. *Endocr Rev* 25:341–373
4. Finn CA 1987 Why do women and some other primates menstruate? *Perspect Biol Med* 30:566–574
5. Kothapalli R, Buyuksal I, Wu SQ, Chegini N, Tabibzadeh S 1997 Detection of eba1, a novel human gene of the transforming growth factor  $\beta$  superfamily association of



- gene expression with endometrial bleeding. *J Clin Invest* 99:2342–2350
6. Salamonsen LA, Lathbury LJ 2000 Endometrial leukocytes and menstruation. *Hum Reprod Update* 6:16–27
  7. Jones RL, Hannan NJ, Kaitu'u TJ, Zhang J, Salamonsen LA 2004 Identification of chemokines important for leukocyte recruitment to the human endometrium at the times of embryo implantation and menstruation. *J Clin Endocrinol Metab* 89:6155–6167
  8. Critchley HO, Kelly RW, Brenner RM, Baird DT 2001 The endocrinology of menstruation—a role for the immune system. *Clin Endocrinol (Oxf)* 55:701–710
  9. Marbaix E, Kokorine I, Moulin P, Donnez J, Eeckhout Y, Courtoy PJ 1996 Menstrual breakdown of human endometrium can be mimicked in vitro and is selectively and reversibly blocked by inhibitors of matrix metalloproteinases. *Proc Natl Acad Sci USA* 93:9120–9125
  10. Dahmoun M, Boman K, Cajander S, Westin P, Backstrom T 1999 Apoptosis, proliferation, and sex hormone receptors in superficial parts of human endometrium at the end of the secretory phase. *J Clin Endocrinol Metab* 84:1737–1743
  11. Kokawa K, Shikone T, Nakano R 1996 Apoptosis in the human uterine endometrium during the menstrual cycle. *J Clin Endocrinol Metab* 81:4144–4147
  12. Rasweiler JJ 1991 Spontaneous decidual reactions and menstruation in the black mastiff bat, *Molossus ater*. *Am J Anat* 191:1–22
  13. Brasted M, White CA, Kennedy TG, Salamonsen LA 2003 Mimicking the events of menstruation in the murine uterus. *Biol Reprod* 69:1273–1280
  14. Christian M, Marangos P, Mak I, McVey J, Barker F, White J, Brosens JJ 2001 Interferon- $\gamma$  modulates prolactin and tissue factor expression in differentiating human endometrial stromal cells. *Endocrinology* 142:3142–3151
  15. Schatz F, Krikun G, Caze R, Rahman M, Lockwood CJ 2003 Progesterone-regulated expression of tissue factor in decidual cells: implications in endometrial hemostasis, menstruation and angiogenesis. *Steroids* 68:849–860
  16. Telgmann R, Maronde E, Tasken K, Gellersen B 1997 Activated protein kinase A is required for differentiation-dependent transcription of the decidual prolactin gene in human endometrial stromal cells. *Endocrinology* 138:929–937
  17. Brosens JJ, Hayashi N, White JO 1999 Progesterone receptor regulates decidual prolactin expression in differentiating human endometrial stromal cells. *Endocrinology* 140:4809–4820
  18. Gellersen B, Brosens J 2003 Cyclic AMP and progesterone receptor cross-talk in human endometrium: a decidualizing affair. *J Endocrinol* 178:357–372
  19. Christian M, Zhang X, Schneider-Merck T, Unterman TG, Gellersen B, White JO, Brosens JJ 2002 Cyclic AMP-induced forkhead transcription factor, FKHR, cooperates with CCAAT/enhancer-binding protein  $\beta$  in differentiating human endometrial stromal cells. *J Biol Chem* 277:20825–20832
  20. Kops GJ, de Ruiter ND, De Vries-Smits AM, Powell DR, Bos JL, Burgering BM 1999 Direct control of the Forkhead transcription factor AFX by protein kinase B. *Nature* 398:630–634
  21. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME 1999 Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. *Cell* 96:857–868
  22. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, Coffey PJ 2000 Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). *Mol Cell Biol* 20:9138–9148
  23. Medema RH, Kops GJ, Bos JL, Burgering BM 2000 AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. *Nature* 404:782–787
  24. Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffey PJ 2000 Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. *Curr Biol* 10:1201–1204
  25. Sunter A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, Coffey PJ, Medema RH, Coombes RC, Lam EW 2003 FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. *J Biol Chem* 278:49795–49805
  26. Sahara T, Kim HS, Kirshenbaum LA, Walsh K 2002 Suppression of Akt signaling induces Fas ligand expression: involvement of caspase and Jun kinase activation in Akt-mediated Fas ligand regulation. *Mol Cell Biol* 22:680–691
  27. Essafi A, Fernandez de Mattos S, Hassen YA, Soeiro I, Mufti GJ, Thomas NS, Medema RH, Lam EW 2005 Direct transcriptional regulation of Bim by FoxO3a mediates STI571-induced apoptosis in Bcr-Abl-expressing cells. *Oncogene* 24:2317–2329
  28. Coffey PJ, Burgering BM 2004 Forkhead-box transcription factors and their role in the immune system. *Nat Rev Immunol* 4:889–899
  29. Pohnke Y, Schneider-Merck T, Fahnenstich J, Kempf R, Christian M, Milde-Langosch K, Brosens JJ, Gellersen B 2004 Wild-type p53 protein is up-regulated upon cyclic adenosine monophosphate-induced differentiation of human endometrial stromal cells. *J Clin Endocrinol Metab* 89:5233–5244
  30. Patterson GI 2003 Aging: new targets, new functions. *Curr Biol* 13:R279–R281
  31. Nemoto S, Fergusson MM, Finkel T 2004 Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. *Science* 306:2105–2108
  32. Accili D, Arden KC 2004 FoxOs at the crossroads of cellular metabolism, differentiation, and transformation. *Cell* 117:421–426
  33. Matsui N, Kawano Y, Nakamura S, Miyakawa I 2004 Changes in vascular endothelial growth factor production associated with decidualization by human endometrial stromal cells in vitro. *Acta Obstet Gynecol Scand* 83:138–143
  34. Gao JG, Zhu HH, Fan J, Mazella J, Tseng L 1995 Progesterone and antiprogesterone differentially regulate the expression of insulin-like growth factors (IGF-I and IGF-II) messenger ribonucleic acid in human endometrial stromal cells. *Biol Reprod* 53:355–360
  35. Matsuzaki H, Daitoku H, Hatta M, Tanaka K, Fukamizu A 2003 Insulin-induced phosphorylation of FKHR (Foxo1) targets to proteasomal degradation. *Proc Natl Acad Sci USA* 100:11285–11290
  36. Plas DR, Thompson CB 2003 Akt activation promotes degradation of tuberin and FOXO3a via the proteasome. *J Biol Chem* 278:12361–12366
  37. Huang H, Regan KM, Wang F, Wang D, Smith DI, van Deursen JM, Tindall DJ 2005 Skp2 inhibits FOXO1 in tumor suppression through ubiquitin-mediated degradation. *Proc Natl Acad Sci USA* 102:1649–1654
  38. Lahav-Baratz S, Ben-Izhak O, Sabo E, Ben-Eliezer S, Lavie O, Ishai D, Ciechanover A, Dirnfeld M 2004 Decreased level of the cell cycle regulator p27 and increased level of its ubiquitin ligase Skp2 in endometrial carcinoma but not in normal secretory or in hyperstimulated endometrium. *Mol Hum Reprod* 10:567–572
  39. Kim JJ, Taylor HS, Akbas GE, Foucher I, Trembleau A, Jaffee RC, Fazleabas AT, Unterman TG 2003 Regulation of insulin-like growth factor binding protein-1 promoter activity by FKHR and HOXA10 in primate endometrial cells. *Biol Reprod* 68:24–30
  40. Chatzaki E, Makrigiannakis A, Margioris AN, Kouimtoglou E, Gravanis A 2001 The Fas/FasL apoptotic path-

- way is involved in  $\kappa$ -opioid-induced apoptosis of human endometrial stromal cells. *Mol Hum Reprod* 7:867–874
41. Kayisli UA, Selam B, Guzeloglu-Kayisli O, Demir R, Arici A 2003 Human chorionic gonadotropin contributes to maternal immunotolerance and endometrial apoptosis by regulating Fas-Fas ligand system. *J Immunol* 171:2305–2313
  42. Kau TR, Schroeder F, Ramaswamy S, Wojciechowski CL, Zhao JJ, Roberts TM, Clardy J, Sellers WR, Silver PA 2003 A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. *Cancer Cell* 4:463–476
  43. Giudice LC, Kao LC Endometriosis 2004 *Lancet* 364:1789–1799
  44. Shazand K, Baban S, Prive C, Malette B, Croteau P, Lagace M, Racine JB, Hugo P 2004 FOXO1 and c-jun transcription factors mRNA are modulated in endometriosis. *Mol Hum Reprod* 10:871–877
  45. Gebel HM, Braun DP, Tambur A, Frame D, Rana N, Dmowski WP 1998 Spontaneous apoptosis of endometrial tissue is impaired in women with endometriosis. *Fertil Steril* 69:1042–1047
  46. Dmowski WP, Ding J, Shen J, Rana N, Fernandez BB, Braun DP 2001 Apoptosis in endometrial glandular and stromal cells in women with and without endometriosis. *Hum Reprod* 16:1802–1808
  47. Kong D, Suzuki A, Zou TT, Sakurada A, Kemp LW, Watatsuki S, Yokoyama T, Yamakawa H, Furukawa T, Sato M, Ohuchi N, Sato S, Yin J, Wang S, Abraham JM, Souza RF, Smolinski KM, Meltzer SJ, Horii A 1997 PTEN1 is frequently mutated in primary endometrial carcinomas. *Nat Genet* 17:143–144
  48. Tashiro H, Blazes MS, Wu R, Cho KR, Bose S, Wang SI, Li J, Parsons R, Ellenson LH 1997 Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. *Cancer Res* 57:3935–3940
  49. Zoumpoulidou G, Jones MC, Fernandez de Mattos S, Francis JM, Fusi L, Lee YS, Christian M, Varshochi R, Lam EW, Brosens JJ 2004 Convergence of interferon- $\gamma$  and progesterone signaling pathways in human endometrium: role of PIASy (protein inhibitor of activated signal transducer and activator of transcription- $\gamma$ ). *Mol Endocrinol* 18:1988–1999
  50. Christian M, Pohnke Y, Kempf R, Gellersen B, Brosens JJ 2002 Functional association of PR and CCAAT/enhancer-binding protein  $\beta$  isoforms: promoter-dependent cooperation between PR-B and liver-enriched inhibitory protein, or liver-enriched activatory protein and PR-A in human endometrial stromal cells. *Mol Endocrinol* 16:141–154



**Molecular Endocrinology** is published monthly by The Endocrine Society (<http://www.endo-society.org>), the foremost professional society serving the endocrine community.